Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Cediranib phase-II study in children with metastatic alveolar soft-part sarcoma (ASPS).

Cohen JW, Widemann BC, Derdak J, Dombi E, Goodwin A, Dompierre J, Onukwubiri U, Steinberg SM, O'Sullivan Coyne G, Kummar S, Chen AP, Glod J.

Pediatr Blood Cancer. 2019 Sep 10:e27987. doi: 10.1002/pbc.27987. [Epub ahead of print]

PMID:
31502400
2.

A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction.

Takebe N, Beumer JH, Kummar S, Kiesel BF, Dowlati A, O'Sullivan Coyne G, Piekarz R, Rubinstein L, Fogli LK, Vaishampayan U, Goel S, O'Bryant CL, El-Rayes BF, Chung V, Lenz HJ, Kim R, Belani CP, Tuscano JM, Schelman W, Moore N, Doroshow JH, Chen AP.

Br J Clin Pharmacol. 2019 Jul 4. doi: 10.1111/bcp.14054. [Epub ahead of print]

PMID:
31271459
3.

First-in-human phase 0 study of 111In-CHX-A"-DTPA trastuzumab for HER2 tumor imaging.

Kurdziel KA, Mena E, McKinney Y, Wong K, Adler S, Sissung T, Lee J, Lipkowitz S, Lindenberg L, Turkbey B, Kummar S, Milenic DE, Doroshow JH, Figg WD, Merino MJ, Paik CH, Brechbiel MW, Choyke PL.

J Transl Sci. 2019 Apr;5(2). doi: 10.15761/JTS.1000269. Epub 2018 Jul 13.

4.

Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers.

Wilsker DF, Barrett AM, Dull AB, Lawrence SM, Hollingshead MG, Chen A, Kummar S, Parchment RE, Doroshow JH, Kinders RJ.

Clin Cancer Res. 2019 May 15;25(10):3084-3095. doi: 10.1158/1078-0432.CCR-18-2523. Epub 2019 Feb 21.

PMID:
30792217
5.

Reviewing the role of healthy volunteer studies in drug development.

Karakunnel JJ, Bui N, Palaniappan L, Schmidt KT, Mahaffey KW, Morrison B, Figg WD, Kummar S.

J Transl Med. 2018 Dec 4;16(1):336. doi: 10.1186/s12967-018-1710-5. Review.

6.

Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine in Solid Tumors.

Young CR, Adler S, Eary JF, Lindenberg ML, Jacobs PM, Collins J, Kummar S, Kurdziel KA, Choyke PL, Mena E.

J Nucl Med. 2019 Apr;60(4):492-496. doi: 10.2967/jnumed.118.216994. Epub 2018 Nov 2.

PMID:
30389817
7.

TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.

Kummar S, Lassen UN.

Target Oncol. 2018 Oct;13(5):545-556. doi: 10.1007/s11523-018-0590-1. Review.

PMID:
30276762
8.

Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion.

Farago AF, Taylor MS, Doebele RC, Zhu VW, Kummar S, Spira AI, Boyle TA, Haura EB, Arcila ME, Benayed R, Aisner DL, Horick NK, Lennerz JK, Le LP, Iafrate AJ, Ou SI, Shaw AT, Mino-Kenudson M, Drilon A.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00037. Epub 2018 Jul 23.

9.

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study.

Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick JJ, Barve M, Daniels GA, Wong DJ, Schmidt EV, Candia AF, Coffman RL, Leung ACF, Janssen RS.

Cancer Discov. 2018 Oct;8(10):1250-1257. doi: 10.1158/2159-8290.CD-18-0280. Epub 2018 Aug 28.

10.

A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas.

Meehan R, Kummar S, Do K, O'Sullivan Coyne G, Juwara L, Zlott J, Rubinstein L, Doroshow JH, Chen AP.

Oncologist. 2018 Nov;23(11):1269-e125. doi: 10.1634/theoncologist.2018-0203. Epub 2018 May 31.

11.

Cation-induced folding of alginate-bearing bilayer gels: an unusual example of spontaneous folding along the long axis.

Athas JC, Nguyen CP, Kummar S, Raghavan SR.

Soft Matter. 2018 Apr 4;14(14):2735-2743. doi: 10.1039/C8SM00321A.

PMID:
29565078
12.

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM.

N Engl J Med. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448.

13.

Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization.

Mullins M, Jiang X, Bylsma LC, Fryzek JP, Reichert H, Chen EC, Kummar S, Rosenthal A.

Blood Adv. 2017 May 19;1(13):839-848. doi: 10.1182/bloodadvances.2017004390. eCollection 2017 May 23.

14.

The evolving paradigm of cancer trials.

Kummar S.

Nat Rev Drug Discov. 2018 Apr;17(4):225-226. doi: 10.1038/nrd.2017.210. Epub 2017 Dec 22. Review. No abstract available.

PMID:
29269944
15.

Molecular insights into desmoid tumors.

Bui N, Kummar S.

Oncotarget. 2017 Sep 28;8(53):90608-90609. doi: 10.18632/oncotarget.21293. eCollection 2017 Oct 31. No abstract available.

16.

Evolution of early phase clinical trials in oncology.

Bui NQ, Kummar S.

J Mol Med (Berl). 2018 Jan;96(1):31-38. doi: 10.1007/s00109-017-1612-7. Epub 2017 Nov 24. Review.

PMID:
29177698
17.

Dosimetry and first human experience with 89Zr-panitumumab.

Lindenberg L, Adler S, Turkbey IB, Mertan F, Ton A, Do K, Kummar S, Gonzalez EM, Bhattacharyya S, Jacobs PM, Choyke P.

Am J Nucl Med Mol Imaging. 2017 Sep 1;7(4):195-203. eCollection 2017.

18.

First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile.

Speranza G, Anderson L, Chen AP, Do K, Eugeni M, Weil M, Rubinstein L, Majerova E, Collins J, Horneffer Y, Juwara L, Zlott J, Bishop R, Conley BA, Streicher H, Tomaszewski J, Doroshow JH, Kummar S.

Invest New Drugs. 2018 Apr;36(2):230-239. doi: 10.1007/s10637-017-0495-3. Epub 2017 Aug 12.

19.

Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial.

Mohrbacher AM, Yang AS, Groshen S, Kummar S, Gutierrez ME, Kang MH, Tsao-Wei D, Reynolds CP, Newman EM, Maurer BJ.

Clin Cancer Res. 2017 Aug 15;23(16):4550-4555. doi: 10.1158/1078-0432.CCR-17-0234. Epub 2017 Apr 18.

20.

A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma.

Goncalves PH, Heilbrun LK, Barrett MT, Kummar S, Hansen AR, Siu LL, Piekarz RL, Sukari AW, Chao J, Pilat MJ, Smith DW, Casetta L, Boerner SA, Chen A, Lenkiewicz E, Malasi S, LoRusso PM.

Oncotarget. 2017 May 16;8(20):32918-32929. doi: 10.18632/oncotarget.16464.

21.

Antibody-independent capture of circulating tumor cells of non-epithelial origin with the ApoStream® system.

Balasubramanian P, Kinders RJ, Kummar S, Gupta V, Hasegawa D, Menachery A, Lawrence SM, Wang L, Ferry-Galow K, Davis D, Parchment RE, Tomaszewski JE, Doroshow JH.

PLoS One. 2017 Apr 12;12(4):e0175414. doi: 10.1371/journal.pone.0175414. eCollection 2017.

22.

Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).

Kummar S, O'Sullivan Coyne G, Do KT, Turkbey B, Meltzer PS, Polley E, Choyke PL, Meehan R, Vilimas R, Horneffer Y, Juwara L, Lih A, Choudhary A, Mitchell SA, Helman LJ, Doroshow JH, Chen AP.

J Clin Oncol. 2017 May 10;35(14):1561-1569. doi: 10.1200/JCO.2016.71.1994. Epub 2017 Mar 28.

23.

Utility of 18F-fluoroestradiol (18F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy.

Lin FI, Gonzalez EM, Kummar S, Do K, Shih J, Adler S, Kurdziel KA, Ton A, Turkbey B, Jacobs PM, Bhattacharyya S, Chen AP, Collins JM, Doroshow JH, Choyke PL, Lindenberg ML.

Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):500-508. doi: 10.1007/s00259-016-3561-8. Epub 2016 Nov 21.

PMID:
27872957
24.

The root causes of pharmacodynamic assay failure.

Ferry-Galow KV, Makhlouf HR, Wilsker DF, Lawrence SM, Pfister TD, Marrero AM, Bigelow KM, Yutzy WH, Ji JJ, Butcher DO, Gouker BA, Kummar S, Chen AP, Kinders RJ, Parchment RE, Doroshow JH.

Semin Oncol. 2016 Aug;43(4):484-91. doi: 10.1053/j.seminoncol.2016.06.006. Epub 2016 Jun 15. Review.

PMID:
27663480
25.

Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells.

Wang L, Balasubramanian P, Chen AP, Kummar S, Evrard YA, Kinders RJ.

Semin Oncol. 2016 Aug;43(4):464-75. doi: 10.1053/j.seminoncol.2016.06.004. Epub 2016 Jun 15. Review.

26.

Establishing proof of mechanism: Assessing target modulation in early-phase clinical trials.

Kummar S, Do K, Coyne GO, Chen A, Ji J, Rubinstein L, Doroshow JH.

Semin Oncol. 2016 Aug;43(4):446-52. doi: 10.1053/j.seminoncol.2016.06.002. Epub 2016 Jun 14. Review.

PMID:
27663476
27.

LC-MS/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasma.

Holleran JL, Eiseman JL, Parise RA, Kummar S, Beumer JH.

J Pharm Biomed Anal. 2016 Sep 10;129:359-366. doi: 10.1016/j.jpba.2016.07.027. Epub 2016 Jul 18.

28.

Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.

Kummar S, Chen A, Gutierrez M, Pfister TD, Wang L, Redon C, Bonner WM, Yutzy W, Zhang Y, Kinders RJ, Ji J, Allen D, Covey JM, Eiseman JL, Holleran JL, Beumer JH, Rubinstein L, Collins J, Tomaszewski J, Parchment R, Pommier Y, Doroshow JH.

Cancer Chemother Pharmacol. 2016 Jul;78(1):73-81. doi: 10.1007/s00280-016-2998-6. Epub 2016 May 11.

29.

Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer.

Kummar S, Wade JL, Oza AM, Sullivan D, Chen AP, Gandara DR, Ji J, Kinders RJ, Wang L, Allen D, Coyne GO, Steinberg SM, Doroshow JH.

Invest New Drugs. 2016 Jun;34(3):355-63. doi: 10.1007/s10637-016-0335-x. Epub 2016 Mar 21.

30.

Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma.

Tricoli JV, Blair DG, Anders CK, Bleyer WA, Boardman LA, Khan J, Kummar S, Hayes-Lattin B, Hunger SP, Merchant M, Seibel NL, Thurin M, Willman CL.

Cancer. 2016 Apr 1;122(7):1017-28. doi: 10.1002/cncr.29871. Epub 2016 Feb 5. Review.

31.

Gastric cancer: Geographic differences in multidisciplinary management.

Kummar S.

Curr Probl Cancer. 2015 Nov-Dec;39(6):314. doi: 10.1016/j.currproblcancer.2015.11.001. Epub 2015 Dec 2. No abstract available.

PMID:
26651626
32.

Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial.

Lih CJ, Sims DJ, Harrington RD, Polley EC, Zhao Y, Mehaffey MG, Forbes TD, Das B, Walsh WD, Datta V, Harper KN, Bouk CH, Rubinstein LV, Simon RM, Conley BA, Chen AP, Kummar S, Doroshow JH, Williams PM.

J Mol Diagn. 2016 Jan;18(1):51-67. doi: 10.1016/j.jmoldx.2015.07.006. Epub 2015 Nov 18.

33.

Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy.

OʼSullivan Coyne G, Chen A, Kummar S.

Curr Opin Oncol. 2015 Nov;27(6):475-81. doi: 10.1097/CCO.0000000000000238. Review.

34.

Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use.

Srivastava AK, Jaganathan S, Stephen L, Hollingshead MG, Layhee A, Damour E, Govindharajulu JP, Donohue J, Esposito D, Mapes JP, Kinders RJ, Takebe N, Tomaszewski JE, Kummar S, Doroshow JH, Parchment RE.

Clin Cancer Res. 2016 Feb 15;22(4):1000-10. doi: 10.1158/1078-0432.CCR-14-3156. Epub 2015 Oct 7.

35.

Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans.

Holleran JL, Beumer JH, McCormick DL, Johnson WD, Newman EM, Doroshow JH, Kummar S, Covey JM, Davis M, Eiseman JL.

Cancer Chemother Pharmacol. 2015 Oct;76(4):803-11. doi: 10.1007/s00280-015-2857-x. Epub 2015 Sep 1.

36.

Inhibitory Effect of the Noncamptothecin Topoisomerase I Inhibitor LMP-400 on Female Mice Models and Human Pheochromocytoma Cells.

Schovanek J, Bullova P, Tayem Y, Giubellino A, Wesley R, Lendvai N, Nölting S, Kopacek J, Frysak Z, Pommier Y, Kummar S, Pacak K.

Endocrinology. 2015 Nov;156(11):4094-104. doi: 10.1210/en.2015-1476. Epub 2015 Aug 12.

37.

Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors.

Do K, Speranza G, Chang LC, Polley EC, Bishop R, Zhu W, Trepel JB, Lee S, Lee MJ, Kinders RJ, Phillips L, Collins J, Lyons J, Jeong W, Antony R, Chen AP, Neckers L, Doroshow JH, Kummar S.

Invest New Drugs. 2015 Aug;33(4):921-30. doi: 10.1007/s10637-015-0255-1. Epub 2015 Jun 18.

PMID:
26082332
38.

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.

Do K, Wilsker D, Ji J, Zlott J, Freshwater T, Kinders RJ, Collins J, Chen AP, Doroshow JH, Kummar S.

J Clin Oncol. 2015 Oct 20;33(30):3409-15. doi: 10.1200/JCO.2014.60.4009. Epub 2015 May 11.

39.

A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer.

Do K, Cao L, Kang Z, Turkbey B, Lindenberg ML, Larkins E, Holkova B, Steinberg SM, Raffeld M, Peer CJ, Figg WD, Eugeni M, Jacobs P, Choyke P, Wright JJ, Doroshow JH, Kummar S.

Clin Colorectal Cancer. 2015 Sep;14(3):154-61. doi: 10.1016/j.clcc.2015.02.007. Epub 2015 Mar 7.

40.

GeneMed: An Informatics Hub for the Coordination of Next-Generation Sequencing Studies that Support Precision Oncology Clinical Trials.

Zhao Y, Polley EC, Li MC, Lih CJ, Palmisano A, Sims DJ, Rubinstein LV, Conley BA, Chen AP, Williams PM, Kummar S, Doroshow JH, Simon RM.

Cancer Inform. 2015 Mar 19;14(Suppl 2):45-55. doi: 10.4137/CIN.S17282. eCollection 2015. Review.

41.

Application of molecular profiling in clinical trials for advanced metastatic cancers.

Kummar S, Williams PM, Lih CJ, Polley EC, Chen AP, Rubinstein LV, Zhao Y, Simon RM, Conley BA, Doroshow JH.

J Natl Cancer Inst. 2015 Feb 6;107(4). pii: djv003. doi: 10.1093/jnci/djv003. Print 2015 Apr.

42.

Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer.

Do K, Speranza G, Bishop R, Khin S, Rubinstein L, Kinders RJ, Datiles M, Eugeni M, Lam MH, Doyle LA, Doroshow JH, Kummar S.

Invest New Drugs. 2015 Jun;33(3):720-8. doi: 10.1007/s10637-015-0212-z. Epub 2015 Feb 1.

PMID:
25637165
43.

Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.

Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, Villalona-Calero MA, Morgan RJ Jr, Szabo PM, Youn A, Chen AP, Ji J, Allen DE, Lih CJ, Mehaffey MG, Walsh WD, McGregor PM 3rd, Steinberg SM, Williams PM, Kinders RJ, Conley BA, Simon RM, Doroshow JH.

Clin Cancer Res. 2015 Apr 1;21(7):1574-82. doi: 10.1158/1078-0432.CCR-14-2565. Epub 2015 Jan 14.

44.

A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine.

Newman EM, Morgan RJ, Kummar S, Beumer JH, Blanchard MS, Ruel C, El-Khoueiry AB, Carroll MI, Hou JM, Li C, Lenz HJ, Eiseman JL, Doroshow JH.

Cancer Chemother Pharmacol. 2015 Mar;75(3):537-46. doi: 10.1007/s00280-014-2674-7. Epub 2015 Jan 8.

45.

New, tolerable γ-secretase inhibitor takes desmoid down a notch.

Hughes DP, Kummar S, Lazar AJ.

Clin Cancer Res. 2015 Jan 1;21(1):7-9. doi: 10.1158/1078-0432.CCR-14-1660. Epub 2014 Oct 21.

46.

Translational research in oncology--10 years of progress and future prospects.

Doroshow JH, Kummar S.

Nat Rev Clin Oncol. 2014 Nov;11(11):649-62. doi: 10.1038/nrclinonc.2014.158. Epub 2014 Oct 7. Review.

PMID:
25286976
47.

Paraneoplastic neurologic manifestations of malignancies. Foreword.

Kummar S.

Curr Probl Cancer. 2014 Jul-Aug;38(4):114. doi: 10.1016/j.currproblcancer.2014.08.001. Epub 2014 Aug 12. No abstract available.

PMID:
25239544
48.

Validation of a hypoxia-inducible factor-1 alpha specimen collection procedure and quantitative enzyme-linked immunosorbent assay in solid tumor tissues.

Park SR, Kinders RJ, Khin S, Hollingshead M, Antony S, Parchment RE, Tomaszewski JE, Kummar S, Doroshow JH.

Anal Biochem. 2014 Aug 15;459:1-11. doi: 10.1016/j.ab.2014.04.025. Epub 2014 May 4.

49.

Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma.

Yavuz S, Apolo AB, Kummar S, del Rivero J, Madan RA, Shawker T, Reynolds J, Celi FS.

Thyroid. 2014 Aug;24(8):1223-31. doi: 10.1089/thy.2013.0621. Epub 2014 Jun 5.

50.

These tumors can be associated with known genetic syndromes, such as the von Hippel-Lindau or multiple endocrine neoplasia 2 syndromes, or they can arise sporadically. Foreword.

Kummar S.

Curr Probl Cancer. 2014 Jan-Feb;38(1):6. doi: 10.1016/j.currproblcancer.2014.02.001. Epub 2014 Feb 17. No abstract available.

PMID:
24636753

Supplemental Content

Loading ...
Support Center